Anti-fibrotic treatments for chronic liver diseases: The present and the future
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Liver fibrosis reflects tissue scarring in the liver due to the accumulation of excessive extracellular matrix in response to chronically persistent liver injury. Hepatocyte cell death can trigger capillarization of liver sinusoidal endothelial cells, stimulation of immune cells including macrophages and Kupffer cells, and activation of hepatic stellate cells (HSCs), resulting in progression of liver fibrosis. Liver cirrhosis is the terminal state of liver fibrosis and is associated with severe complications, such as liver failure, portal hypertension, and liver cancer. Nevertheless, effective therapy for cirrhosis has not yet been established, and liver transplantation is the only radical treatment for severe cases. Studies investigating HSC activation and regulation of collagen production in the liver have made breakthroughs in recent decades that have advanced the knowledge regarding liver fibrosis pathophysiology. In this review, we summarize molecular mechanisms of liver fibrosis and discuss the development of novel anti-fibrotic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“A randomized phase 3 clinical trial of pioglitazone, a synthetic insulin sensitizing PPARγ agonist, reported improved steatosis and lobular inflammation without a significant effect on fibrosis, in non-cirrhotic NASH patients.(21) However, a subsequent meta-analysis of eight randomized clinical trials for thiazolidine…”
BackgroundInflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295 · cited 1×
“Hepatocyte cell death caused by chronic liver injury causes inflammatory activity of liver immune cells, predominantly macrophages, leading to an increase in these secretory factors.(17) In addition, pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharides released from microbes, DNA, and damaged-ass…”
BackgroundYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets
Drummond, G. R., Selemidis, S., Griendling, K. K., & Sobey, C. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3403 · Cited by 899
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ
Iredale, J. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30542 · Cited by 866 · cited 1×
“Liver fibrosis is the most common pathology of cirrhosis and is characterized by progressive accumulation of extracellular matrix (ECM), which destroys the lobule architecture of the liver.(5) Most of the liver injury is associated with hepatocyte damage.”
BackgroundHarrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
Karlmark, K. R., Weiskirchen, R., Zimmermann, H. W., Gassler, N., Ginhoux, F., Weber, C., Merad, M., Luedde, T., Trautwein, C., & Tacke, F. (2009) · Hepatology · doi:10.1002/hep.22950 · Cited by 782
The inflammasome: an integrated view
Gross, O., Thomas, C. J., Guarda, G., & Tschopp, J. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01046.x · Cited by 778
Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671 · cited 1×
“Moreover, a phase 2b randomized study (NCT02217475) has reported that after 1 year of CVC treatment, twice as many subjects achieved an improvement in fibrosis without worsening of steatohepatitis, compared with placebo.(76) A rollover study using CVC for the treatment of liver fibrosis in NASH patients is ongoing (NC…”
ResultPradere, J.-P., Kluwe, J., De Minicis, S., Jiao, J.-J., Gwak, G.-Y., Dapito, D. H., Jang, M.-K., Guenther, N. D., Mederacke, I., Friedman, R., et al. (2013) · Hepatology · doi:10.1002/hep.26429 · Cited by 613 · cited 1×
“Pro-inflammatory cytokines released from the macrophages activate HSCs by promoting collagen production.(73) In fact, a dual CCR2/CCR5 inhibitor, cenicriviroc (CVC) reportedly reduced recruitment of pro-inflammatory macrophages and exerted anti-fibrotic effects in animal models of liver fibrosis.”
BackgroundSanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31785-9 · Cited by 550
Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., & Seki, E. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00365.2011 · Cited by 503 · cited 1×
“In response to liver injury, Kupffer cells secrete CCL2 and promote monocyte recruitment to the liver, followed by their maturation into pro-inflammatory LY6C macrophages.(71,72) Pro-inflammatory cytokines released from the macrophages activate HSCs by promoting collagen production.”
BackgroundHarrison, S. A., Wong, V. W.-S., Okanoue, T., Bzowej, N., Vuppalanchi, R., Younes, Z., Kohli, A., Sarin, S., Caldwell, S. H., Alkhouri, N., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.027 · Cited by 497
Self-citationDeterminants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479 · cited 8×
“Oxidative stress is a known cause of liver fibrosis progression, particularly in NASH.34 NADPH oxidase (NOX) is a common source of reactive oxygen species (ROS) generation,35,36 and NOX1, 2, and 4 play important roles in the activation of HSCs.37,38 GKT137831, a NOX1/4 inhibitor, suppresses ROS production, NOX, and fi…”
BackgroundInfluentialThiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449
CCR1 and CCR5 promote hepatic fibrosis in mice
Seki, E., De Minicis, S., Gwak, G.-Y., Kluwe, J., Inokuchi, S., Bursill, C. A., Llovet, J. M., Brenner, D. A., & Schwabe, R. F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37444 · Cited by 431
Bile Acids as Hormones: The FXR-FGF15/19 Pathway
Kliewer, S. A., & Mangelsdorf, D. J. (2015) · Digestive Diseases · doi:10.1159/000371670 · Cited by 424
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
D'Ambrosio, R., Aghemo, A., Rumi, M. G., Ronchi, G., Donato, M. F., Paradis, V., Colombo, M., & Bedossa, P. (2012) · Hepatology · doi:10.1002/hep.25606 · Cited by 409 · cited 1×
“A study reported that 50–60% of cirrhosis patients who achieved SVR by interferon therapy experienced histological regression of liver fibrosis.(12,130) Patients who achieved SVR following treatment with direct-acting antiviral agents also experienced liver fibrosis regression.”
BackgroundStatin use and non-alcoholic steatohepatitis in at risk individuals
Dongiovanni, P., Petta, S., Mannisto, V., Mancina, R. M., Pipitone, R., Karja, V., Maggioni, M., Kakela, P., Wiklund, O., Mozzi, E., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.006 · Cited by 390
Harrison, S. A., Abdelmalek, M. F., Caldwell, S., Shiffman, M. L., Diehl, A. M., Ghalib, R., Lawitz, E. J., Rockey, D. C., Schall, R. A., Jia, C., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.006 · Cited by 384
The NOX toolbox: validating the role of NADPH oxidases in physiology and disease
Altenhöfer, S., Kleikers, P. W. M., Radermacher, K. A., Scheurer, P., Rob Hermans, J. J., Schiffers, P., Ho, H., Wingler, K., & Schmidt, H. H. H. W. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1010-9 · Cited by 371
Chalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.296 · Cited by 358
Mossanen, J. C., Krenkel, O., Ergen, C., Govaere, O., Liepelt, A., Puengel, T., Heymann, F., Kalthoff, S., Lefebvre, E., Eulberg, D., et al. (2016) · Hepatology · doi:10.1002/hep.28682 · Cited by 325 · cited 1×
“In fact, a dual CCR2/CCR5 inhibitor, cenicriviroc (CVC) reportedly reduced recruitment of pro-inflammatory macrophages and exerted anti-fibrotic effects in animal models of liver fibrosis.(74,75) Moreover, a phase 2b randomized study (NCT02217475) has reported that after 1 year of CVC treatment, twice as many subjects…”
BackgroundLefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158156 · Cited by 323 · cited 1×
“In fact, a dual CCR2/CCR5 inhibitor, cenicriviroc (CVC) reportedly reduced recruitment of pro-inflammatory macrophages and exerted anti-fibrotic effects in animal models of liver fibrosis.(74,75) Moreover, a phase 2b randomized study (NCT02217475) has reported that after 1 year of CVC treatment, twice as many subjects…”
BackgroundCorpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Neutrophils contribute to spontaneous resolution of liver inflammation and fibrosis via microRNA-223
Calvente, C. J., Tameda, M., Johnson, C. D., del Pilar, H., Lin, Y. C., Adronikou, N., De Mollerat Du Jeu, X., Llorente, C., Boyer, J., & Feldstein, A. E. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122258 · Cited by 268 · cited 2×
“Calvente et al.(87) demonstrated that neutrophilderived microRNA-223 acts as a silencer of Nlrp3 in hepatic macrophages, resulting in attenuated fibrogenesis via inhibition of collagen synthesis in HSCs.”
BackgroundA randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
Harrison, S. A., Goodman, Z., Jabbar, A., Vemulapalli, R., Younes, Z. H., Freilich, B., Sheikh, M. Y., Schattenberg, J. M., Kayali, Z., Zivony, A., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.024 · Cited by 260 · cited 1×
“Though emricasan slightly improved HVPG in cirrhotic NASH patients (NCT02960204),(90) it did not improve liver inflammation or fibrosis, but rather had a tendency to worsen hepatocyte ballooning in patients with NASHassociated F1–F3 fibrosis (NCT02686762).(91) Furthermore, emricasan did not meet the primary endpoint i…”
BackgroundCharles, E. D., Neuschwander‐Tetri, B. A., Pablo Frias, J., Kundu, S., Luo, Y., Tirucherai, G. S., & Christian, R. (2019) · Obesity · doi:10.1002/oby.22344 · Cited by 257
Human Hepatic Stellate Cells Express CCR5 and RANTES to Induce Proliferation and Migration
Schwabe, R. F., Bataller, R., & Brenner, D. A. (2003) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00215.2003 · Cited by 252
Jiang, J. X., Chen, X., Serizawa, N., Szyndralewiez, C., Page, P., Schröder, K., Brandes, R. P., Devaraj, S., & Török, N. J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.007 · Cited by 251
Liu, S. B., Ikenaga, N., Peng, Z., Sverdlov, D. Y., Greenstein, A., Smith, V., Schuppan, D., & Popov, Y. (2016) · The FASEB Journal · doi:10.1096/fj.14-268425 · Cited by 224
Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets
Ezhilarasan, D., Sokal, E., & Najimi, M. (2018) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/j.hbpd.2018.04.003 · Cited by 204 · cited 1×
“Therefore, studies on the effectiveness of targeted HSC apoptosis as a therapeutic strategy for liver fibrosis are being actively conducted.(52,53)”
BackgroundMuir, A. J., Levy, C., Janssen, H. L. A., Montano‐Loza, A. J., Shiffman, M. L., Caldwell, S., Luketic, V., Ding, D., Jia, C., McColgan, B. J., et al. (2019) · Hepatology · doi:10.1002/hep.30237 · Cited by 195
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Zhou, M., Wang, X., Phung, V., Lindhout, D. A., Mondal, K., Hsu, J.-Y., Yang, H., Humphrey, M., Ding, X., Arora, T., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0208 · Cited by 183
Thapaliya, S., Wree, A., Povero, D., Inzaugarat, M. E., Berk, M., Dixon, L., Papouchado, B. G., & Feldstein, A. E. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3167-6 · Cited by 162 · cited 1×
“NASH Previous reports have shown that hepatocyte cell death induces liver inflammation and HSC activation, leading to liver fibrosis progression; hence, inhibition of hepatocyte death could decrease HSC activation in animal models.(88,89) Recently, randomized placebo-controlled trials for emricasan, a pan-caspase inhi…”
BackgroundNon-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Zhou, M., Yang, H., Learned, R. M., Tian, H., & Ling, L. (2017) · Nature Communications · doi:10.1038/ncomms15433 · Cited by 123 · cited 1×
“NGM282, an FGF19 analog, inhibits bile acid synthesis without FGF19-related hepatocarcinogenesis.(124,125) In mouse models of NASH, NGM282 exerts anti-steatotic, anti-inflammatory, and antifibrotic effects without promoting liver tumorigenesis.”
BackgroundTranscriptional regulation of hepatic stellate cells
Mann, J., & Mann, D. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.011 · Cited by 119 · cited 6×
“Oxidative stress is a known cause of liver fibrosis progression, particularly in NASH.34 NADPH oxidase (NOX) is a common source of reactive oxygen species (ROS) generation,35,36 and NOX1, 2, and 4 play important roles in the activation of HSCs.37,38 GKT137831, a NOX1/4 inhibitor, suppresses ROS production, NOX, and fi…”
BackgroundInfluentialOkina, Y., Sato-Matsubara, M., Matsubara, T., Daikoku, A., Longato, L., Rombouts, K., Thanh Thuy, L. T., Ichikawa, H., Minamiyama, Y., Kadota, M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.051 · Cited by 49 · cited 1×
“TGF-β1-induced suppression of human CYGB expression is reported to contribute to the promotion of HSC activation via loss of cellular tolerance to exogenous oxidative stress and oxidative DNA damage in HSCs, resulting in acceleration of liver fibrosis.(46) Cygb-deficient mice presented with”
BackgroundSelf-citation
Cited by
Le, M. H., Yeo, Y. H., Zou, B., Barnet, S., Henry, L., Cheung, R., & Nguyen, M. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0239 · Cited by 357
The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities
Binatti, E., Gerussi, A., Barisani, D., & Invernizzi, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126649 · Cited by 62
“, reported that GKT137831 showed significant improvement of liver fibrosis by suppressing ROS production, via NADPH inhibition, and fibrotic gene expression in mice induced by carbon tetrachloride (CCL4) and duct ligation [79,80].”
BackgroundLee, J., Kim, C. M., Cha, J. H., Park, J. Y., Yu, Y. S., Wang, H. J., Sung, P. S., Jung, E. S., & Bae, S. H. (2022) · Cells · doi:10.3390/cells11213387 · Cited by 16
“In an effort to alleviate the burden of chronic liver disease, many studies have sought to find novel biomarkers of advanced liver fibrosis [3].”
Background
Metadata
- Authors
- Odagiri, N., Matsubara, T., Sato-Matsubara, M., Fujii, H., Enomoto, M., & Kawada, N.
- Venue
- Clinical and Molecular Hepatology
- Published
- 2021-07-01
- Volume
- 27
- Issue
- 3
- Pages
- 413-424
- ISSN
- 2287-2728 (ISSN-L)
- 2287-285X
- OpenAlex
- W3112047391
- Cited by
- 61
- References
- 46
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.